Medical Meeting

@MondayNightIBD: Identifying the Factors that Impact Success in Your Practice

Launch Date
10/26/2020
Credit Amount
0.00 Expired
Credit Expires
10/26/2021

Faculty

Aline Charabaty, MD, AGAF
Clinical Director of Gastroenterology
Director of Inflammatory Bowel Disease Center, Sibley Memorial Hospital
Assistant Professor of Medicine, Johns Hopkins School of Medicine, Washington, DC
Aline Charabaty, MD, AGAF

Dr. Aline Charabaty is the Clinical Director of the GI Division and Director of the Inflammatory Bowel Diseases (IBD) Center at Johns Hopkins-Sibley Memorial Hospital. She completed her residency and GI fellowship at Georgetown University Hospital, where she joined the GI faculty and established and led the IBD center for 13 years before joining the Johns Hopkins School of Medicine faculty in January 2019. Dr. Charabaty lectures on IBD at national meetings and has advocated for patients with IBD on the Hill. She also uses social media to educate colleagues and IBD patients. She founded @MondayNightIBD, a twitter platform that brings clinicians together to discuss the management of complex IBD cases, for which she received the Healio Gastroenterology Disruptive Innovator Award during ACG 2019.

Dr. Charabaty has been the Chair of the Greater Washington DC/Virginia Crohns and Colitis Foundation Mission Committee since 2012 and served on the CCF National Scientific Advisory Committee Patient Education and Physician Education Committees. She is actively involved in educational and/or advocacy activities and committees with the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG). Dr. Charabaty was selected as a Washingtonian Top Doctors by her peers on consecutive years.

Christina Ha, MD, FACG, AGAF
Inflammatory Bowel Disease Center Mayo Clinic Scottsdale, AZ
Christina Ha, MD, FACG, AGAF

Christina Ha, MD, FACG, is an Associate Professor with the F. Widjaja Foundation Inflammatory Bowel Immunology Research Institute at Cedars-Sinai She received her BA from Harvard College and her MD from the Albert Einstein College of Medicine in New York. She completed an internal medicine residency and GI fellowship at the Washington University in St. Louis School of Medicine and as the Present-Levison Inflammatory Bowel Diseases Fellow at the Mount Sinai School of Medicine. After fellowship, Dr. Ha joined the faculty as Co-Associate Director of Clinical Research at the Meyerhoff Inflammatory Bowel Disease Center and Associate Fellowship Director for the Division of Gastroenterology and Hepatology at the Johns Hopkins School of Medicine. From there, she joined the Tamar and Vatche Manoukian Division of Digestive Diseases as the Associate Director of Clinical Programs for the Center for Inflammatory Bowel Diseases at the David Geffen School of Medicine prior to moving to Cedars-Sinai. Her clinical research interests focus on the impact of aging on the natural history of inflammatory bowel diseases, particularly with respect to therapeutics, morbidity, and mortality. Dr. Ha is the Director of the IBD Fellowship Program at Cedars-Sinai and has been involved in medical education initiatives locally and nationally.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

@MondayNightIBD brings social media and clinical practice influencers in gastroenterology together in a weekly online conversation that has become an international platform, moving the field of gastroenterology forward. It crowdsources the knowledge and experience of leading inflammatory bowel disease (IBD) experts, community clinicians, and patients to meet the many challenges of IBD.

In this webcast, CME Outfitters and @MondayNightIBD come together to bring you a panel of experts who will tailor a series of patient cases. These cases will focus on the application of cutting-edge data for novel therapies, identifying appropriate treatment strategies for special populations such as young patients and racial/ethnic minorities, and developing patient communication strategies, with the aim of achieving optimal patient outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Apply efficacy, safety, and comparative effectiveness data for existing and emerging therapies to optimize therapy selection for patients with IBD.
  • Identify appropriate treatment strategies for special populations with IBD such as young patients and racial/ethnic minorities.
  • Develop strategies such as disease monitoring, shared decision-making (SDM), and patient education in order to achieve optimal patient outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain efficacy, safety, and comparative effectiveness data for existing and emerging therapies to optimize therapy selection for patients with IBD.
  • Identify appropriate treatment strategies for special populations with IBD such as young patients and racial/ethnic minorities.
  • Identify strategies such as disease monitoring, SDM, and patient education in order to achieve optimal patient outcomes.

Financial Support

Supported by educational grants from AbbVie Inc.; Genentech, a member of the Roche Group; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-20-154-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Charabaty reports that she serves on the advisory committee for Janssen Pharmaceuticals, Inc. She is a consultant for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

Dr. Ha reports that she receives research support from Pfizer Inc. She serves on the advisory committee for AbbVie Inc.; Genentech Inc.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

  • Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
  • Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
  • Olga Askinazi, PhD (planning committee) has no disclosures to report.
  • Susan Perry (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-154-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

 

MMV-108-102620-90

@MondayNightIBD: Identifying the Factors that Impact Success in Your Practice
Event Date: 10/26/2020